reported for the first time that liraglutide exhibited significant anti-proliferation and pro-apoptotic effects on gemcitabine-resistant human pancreatic cancer cells resistant to a variety of drugs, by regulating the NF-B signaling pathway and downstream ATP-binding cassette subfamily G member 2 (ABCG2) (213, 214)
In the SCALE study, liraglutide, administered daily at a dose of 0.63.0 mg, was associated with a body weight loss 5.6 kg greater than placebo [45]
A) all generic cos were very low on their GLP1 forecast before the launch - a few 10s of crores at best in the 1st year eg A top co in India had a 10cr first yr sales forecast and is set to do a multiplier of that On top of that fewer than expected cos have launched B) online sales which is the biggest area of growth on GLP1s (pharmacies / Telehealth) doesnt get captured and so is direct sales
Because these medications reduce appetite and slow stomach emptying, people may eat less and feel full longer, which can lead to lower fluid intake if hydration isnt intentional
Some studies suggest an association, while others do not show a clear increased risk
.png)
